Alteration of Transthyretin Microheterogeneity in Serum of Multiple Trauma Patients by Gericke, Beate et al.
Biomarker Insights 2007: 2 299–306 299
ORIGINAL RESEARCH
Alteration of Transthyretin Microheterogeneity in Serum 
of Multiple Trauma Patients
Beate Gericke1, Jens Raila1, Maria Deja2, Sascha Rohn3, Bernd Donaubauer2, Britta 
Nagl1, Sophie Haebel4, Florian J. Schweigert1 and Udo Kaisers2,
1Department of Physiology and Pathophysiology, Institute of Nutritional Science, University of 
Potsdam. 2Department of Anaesthesiology and Intensive Care Medicine, Charité, Campus Virchow-
Klinikum, Universitätsmedizin Berlin. 3Department of Food Analysis, Institute of Food Technology and 
Food Chemistry, Technical University of Berlin. 4Interdisciplinary Center for Mass Spectrometry of 
Biopolymers, University of Potsdam.
Abstract: Transthyretin (TTR) which exists in various isoforms, is a valid marker for acute phase response and subclinical 
malnutrition. The aim of the study was to investigate the relationship between infl ammation, oxidative stress and the 
occurrence of changes in microheterogeneity of TTR.
A prospective, observational study at a level-I trauma center of a large urban medical university was performed. Patients 
were severely injured (n = 18; injury severity score (ISS): 34–66), and were observed within the fi rst 24 hours of admit-
tance and over the following days until day 20 after injury. 20 healthy subjects, matched by age and sex, were used as 
controls.
TTR was enriched by immunoprecipitation. Microheterogeneity of TTR was determined by linear matrix assisted laser 
desorption/ionization-time of fl ight-mass spectrometry (MALDI-TOF-MS). Four major mass signals were observed for 
TTR representing native, S-cysteinylated, S-cysteinglycinylated and S-glutathionylated TTR. In the course of their ICU 
stay, 14 of the 18 patients showed a transient change in microheterogeneity in favour of the S-cysteinglycinylated form of 
TTR (p < 0.05 vs. controls). The occurrence of this variant was not associated with the severity of trauma or the intensity 
of the acute-phase response, but was associated with oxidative stress as evidenced by Trolox.
Our results demonstrate that changes in microheterogeneity of TTR occur in a substantial number of ICU trauma patients. 
The diagnostic values of these changes remains to be elucidated. It is speculated that TTR modifi cation may well be the 
mechanism underlying the morphological manifestation of amyloidose or Alzheimer’s diseases in patients surviving multiple 
trauma.
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Introduction
Transthyretin (TTR), formerly called prealbumin, belongs to the group of proteins including thyroxine-
binding globulin and albumin, which bind to and transport thyroid hormones in the blood. TTR is also 
involved in the metabolism of vitamin A as it binds retinol-binding protein (RBP), the specifi c serum 
transport protein for retinol. First identifi ed in 1942 by Kabat et al. in serum and cerebrospinal fl uid, TTR 
has been described as a so-called visceral protein that is synthesized in the liver in response to nutritional 
supply. Therefore, TTR serum levels can be used as a sensitive biochemical parameter of subclinical 
malnutrition, since both the synthesis of proteins as well as energy intake are refl ected in its serum levels. 
Serum levels of TTR are however also affected by acute and chronic diseases associated with an acute-
phase response. Under these conditions, liver activity is concentrated on the synthesis of acute-phase 
response proteins, resulting in a drop in visceral proteins despite adequate nutritional supply (Ingenbleek 
and Young, 1994; Lasztity et al. 2002; Power et al. 2000; Abraham et al. 2003). Mutations in the TTR 
gene are the most common cause of autosomal dominant systemic amyloidosis such as the familial 
amyloid polyneuropathy (Quintas et al. 1999; Merlini and Bellotti, 2003). In these amyloidoses, the 
pathological deposits are characterized by the high abundance of TTR-β-structured-fi brils (Merlini and 
Bellotti, 2003). TTR has a single cysteine residue in position 10 that can exist in the SH form or as a 
mixed disulfi de with the amino acid cysteine as well as with the peptides cysteinylglycine and glutathione 
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(Bernstein and Ingenbleek, 2002; Schweigert et al. 
2004). Additionally, Cys10 adducts of the 
S-homocysteine of TTR have been detected in 
serum of humans with hyperhomocysteinemia 
(Sass et al. 2003). It has recently been discussed 
that post-translational modifi cations of TTR repre-
sent a potential risk factor for the development of 
senile systemic amyloidosis (Zhang and Kelly, 
2003). In-vitro TTR modifi ed at the cys10 is found 
to be more susceptible to the formation of fi brils as 
precursors of amyloid deposits (Zhang and Kelly, 
2003). Modifi cations of the TTR molecule might 
not only result in changes in its function but may 
also serve, for instance, as a biochemical marker 
for oxidative stress.
Free radical-derived reactive oxygen species 
(ROS) are constantly generated in living tissues, 
potentially damaging DNA, proteins and lipids. 
“Oxidative stress” occurs if ROS reaches abnor-
mally high concentrations. Several pathological 
conditions such as atherosclerosis, carcinogenesis, 
neurodegenerative diseases, rheumatoid arthritis, 
and cataracts, as well as aging and cell death, have 
been linked to oxidative damage in various cell 
components (Berger, 2005). Antioxidative 
compounds, such as glutathione, play a protective 
role in minimizing the deleterious consequences 
of oxygen activation processes. Essentially, their 
benefi cial effect occurs due to their ability to 
reduce disulfi des or to oxidize themselves to disul-
fi des. Once formed, thiol groups can also generate 
mixed disulfi de bonds with protein thiol residues. 
Thus, besides the potential protection of protein-
cysteine(Cys)-residues from irreversible oxidative 
modifi cations, thiol/disulfi des can recruit protein 
thiol residues for the antioxidative buffering 
system (Tobaben et al. 2003).
Procedures which occur in connection with 
polytrauma induce a host defense response. This 
is characterized by local and systemic release of 
pro-inflammatory cytokines, arachidonic acid 
metabolites, contact phase and coagulation 
proteins, complement factors and acute phase 
proteins, as well as hormonal mediators. It is 
defined as systemic inflammatory response 
syndrome and is determined according to clinical 
parameters. However in parallel, anti-infl amma-
tory mediators are produced (compensatory 
anti-infl ammatory response syndrome) (Keel and 
Trentz, 2005). The production of free radicals is 
supported by several stress factors. Enzymatic 
protecting systems react to oxidative stress by 
positive adaptation. The non-enzymatic antioxida-
tive systems (α-tocopherol, ascorbic acid, selen) 
are diminished, indicating an increased require-
ment (Kreinhoff et al. 1990).
Due to the fact that TTR acts as a negative 
acute-phase protein and based on the assumed 
interaction between changes in its mircrohetero-
geneity through the exchange at the Cys on position 
10 and oxidative stress, we assumed a role for TTR 
modifi cations in acute phase reaction and oxidative 
stress in multiple trauma patients. Therefore, we 
investigated the microheterogeneity of TTR and 
its relation to systemic infl ammation in severely 
trauma patients.
Methods
Patients
A total of 18 severely injured intensive care unit 
(ICU) patients were randomly selected and 
assessed within the fi rst 24 hours after trauma 
and over the following days until day 20. The 
study protocol was approved by the ethic 
committee of the hospital and informed consent 
was obtained from legal substitutes. 20 healthy 
(based on physical and clinical-chemical param-
eters) subjects, matched by age and sex, were 
used as controls. The Injury Severity Score (ISS) 
is an anatomical scoring system whereby the 
score from the 3 most severely injured body 
regions (Head, Face, Chest, Abdomen, Extrem-
ities (including Pelvis), External) is squared and 
added together to produce the ISS score (ISS: 
45 ± 7.5, mean ± SD). Blood samples were taken 
within the fi rst 24 hours and at day 20 after 
injury.
Immunoprecipitation of TTR 
and MALDI-TOF-MS
15 µl of serum was treated with equal amounts 
of a polyclonal rabbit anti human TTR or RBP 
(DakoCytomation, Denmark) and with 15 µl 
Sephadex G-15, 1 mg/ml phosphate buffer saline 
(PBS), (Pharmacia Fine Chemicals, Sweden). The 
mixture was incubated for two hours at 37 °C and 
then centrifuged at 15.000 × g for 15 min at room 
temperature. The supernatant was removed and 
the immunoprecipitated complex of TTR was 
extensively washed three times with PBS and then 
after fi nal centrifugation, it was dissolved in 5 µl 
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PBS. This was followed by a two step preparation 
procedure: Firstly, 1 µl immunoprecipitated 
sample was deposited on the target and dried. 
Secondly, 0.5 µl matrix (a saturated solution of 
sinapinic acid in acetonitrile plus water (1:2; v/v) 
containing 0.1% trifl uoroacetic acid) was placed 
on the serum drop and also dried. This step was 
repeated.
MALDI mass spectra of the immunoprecipi-
tated TTR was obtained using a Refl ex II MALDI-
TOF mass spectrometer (Bruker-Daltonik, 
Bremen, Germany). MALDI-TOF MS was 
performed in linear mode at 20k acceleration 
voltage. For ionisation, a nitrogen laser (VFL-
337ND, LSI, MA, Newton, USA; 337 nm, 3 ns 
pulse width, 3 Hz) was used. The spectra were 
calculated by using external calibration with ions 
produced from horse cytochrome c (m/z 12,360.08) 
and horse myoglobin (m/z 16,951.46). After 
external calibration, this mass spectrometer was 
capable of achieving ~0.1% mass accuracy in the 
linear mode.
The samples were prepared in a two step proce-
dure as follows. To determine the disulfi de linkage 
of TTR adducts, the immunoprecipitated TTR was 
treated with dithiothreitol (DTT). DTT solution 
(100 mM) in buffer (100 mM NH4CO3, pH 8.8) 
was added to the solution at a ratio of 1:1 v/v (DTT 
solution volume/TTR solution volume). The 
mixture was incubated for 2 h at room temperature. 
Thereafter samples were immunoprecipitated as 
described and subsequently subjected to MALDI-
TOF-MS.
Quantitative analysis of C-reactive 
protein (CRP) and TTR
Serum TTR was quantitatively determined by an 
ELISA method using a polyclonal rabbit anti-
human antibody (DakoCytomation, Hamburg, 
Germany). The TTR was measured by use of an 
ELISA technique adapted from the RBP proce-
dure (Schweigert et al. 2003). In detail, wells of 
microtiter plates were coated through the addition 
to each well of rabbit anti-human TTR IgG 
(DakoCytomation, Hamburg, Germany) diluted 
1:2000 in 50 µl of 50 mM carbonate buffer 
(pH 9.6) and then incubated for 2 hours at 37 °C. 
Plates were washed 4 times with PBS-Tween 
(pH 7.4), shaken dry, wrapped in plastic, and 
stored overnight at 4 °C. For analysis, nonspecifi c 
binding was blocked by the addition of 1% BSA 
diluted in PBS and incubated for 2 hours at 37 °C. 
After 4 additional washings, 50 µl of TTR 
standard (N Protein Standard/Standard SL OQIM 
13, Dade Behring GmbH, Marburg, Germany) 
or serum sample diluted with PBS-Tween 
(pH 7.4) was placed in triplicate wells and incu-
bated for 2 hours at 37 °C with constant shaking. 
After rinsing the wells with PBS-Tween (pH 7.4), 
50 µl of peroxidase-conjugated sheep anti-human 
TTR IgG (Biotrend, Cologne, Germany), diluted 
1:2000 in PBS-Tween with 1% BSA was added 
to each well, and plates were incubated for 1 hour 
at 37  °C. After 4 fi nal washings, color was devel-
oped by the addition of o-phenylenediamine 
dihydrochloride solution (OPD, Sigma, Deisen-
hofen, Germany) and incubated for 20 minutes 
at 25 °C. OPD solution (100 µl/well) consisted 
of 3.7 mM solution in 50 mM disodium 
phosphate-25 mM citric acid buffer (pH 5.2) 
containing 0.012% H2O2. The reaction was 
stopped by the addition of 1 M H2SO4 (50 µl/well) 
and absorbance was measured at 490 nm by use 
of a spectrophotometer (Microplate Reader, Bio-
Rad, Munich, Germany). The intra-assay 
coeffi cient of variation was 8.8%, and interassay 
coeffi cient of variation was 8.1%.
CRP levels in serum were measured with a 
high sensitivity latex turbimetric immunoassay 
using a latex-coupled monoclonal mouse anti-
human antibody (Olympus AU 600, Biomed, 
Germany). The sensitivity of this assay was 
0.005 mg/dl. The 90th percentile of normal CRP 
distribution was 0.3 mg/dl.
Trolox equivalent antioxidant capacity 
(TEAC) assay
To measure the antioxidant capacity, the TEAC 
assay, described by Re et al. (Re et al. 1999), was 
used with minor modifi cations. This method is 
based on the reaction of the blue/green stable 
ABTS radical (ABTS*), which is formed through 
the reaction of ABTS and K2O8S2, with antioxi-
dants. In this reaction, the blue/green color 
disappears because the ABTS* reacts with the 
antioxidant. This decolorization is determined 
spectrophotometrically at 734 nm after 6 min. 
The reduction in absorbance is related to that of 
Trolox, a synthetic, hydrophilic vitamin E 
analogue, which gives the TEAC value. The 
TEAC is calculated as millimoles of Trolox 
equivalents per litre.
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Analysis of Carotenoids 
and α-Tocopherol
For separation and quantifi cation of carotenoids 
(α-carotene, β-carotene, lutein, zeaxanthin, 
canthaxanthin, β-cryptoxanthin, lycopene) and 
α-tocopherol, a gradient reversed-phase HPLC-
system was used (Waters, Eschborn, Germany) as 
described in the literature. (Schweigert et al. 2003). 
Results of α-tocopherol and β-carotene were 
compared with the standard reference material 968a 
[National Institute of Standards Technology (NIST), 
Gaithersburg, MD, USA]. Carotenoid standards of 
lutein, zeaxanthin, canthaxanthin, β-cryptoxanthin 
and lycopene were a generous gift from Hoffman-
La Roche, Switzerland and the standards for 
α-carotene, β-carotene and α-tocopherol were from 
Sigma (Deisenhofen, Germany).
Statistical procedures
All data are given as a mean value ± SD. Statistical 
analysis was performed using nonparametric 
procedures. The Mann-Withney U-rank test was 
used to test for signifi cant differences between 
patients and controls. The Wilcoxon test was used 
for the comparison between results of the fi rst 24 
hours and day 20 after injury. Values of p < 0.05 
were considered signifi cant.
Results
Patients studied were predominantly male (age 
32 ± 11 yrs) who had a mean Injury Severity Score 
(ISS) of 45.2 ± 7.5 (Table 1). Levels of TTR did 
not differ within the fi rst 24 hours up to day 20 
after trauma (4.0 ± 2.6 µmol/L vs. 4.1 ± 3.0 µmol/L; 
mean ± SD; n.s.). The CRP values tended to be 
lower on day 20 after injury (13.3 ± 8.4, 6.1 ± 4.6; 
mean ± SD; Table 2).
Four dominant peaks were detected after 
immunoprecipitation by MALDI-TOF-MS 
(external calibration) in the range where TTR 
and its conjugated forms should normally appear 
(m/z 13,700–14,100), with a dominant peak at 
13,878 ± 7 m/z (controls). The molecular mass 
of 13,757 ± 6 Da (controls) corresponded to the 
native, unmodifi ed TTR. The other ion peaks 
showed molecular masses of 121 ± 3, 179 ± 3 
and 298 ±  5 Da larger than native TTR, 
representing Cys10 adducts for S-cysteine 
(TTR-Cys10-S-S-Cys, mass = 13,877 ± 7 Da), 
S-cysteinylglycine (TTR-Cys10-S-S-CysGly, 
mass = 13,934 ± 6) and S-glutathione (TTR- Cys10-
S-S-SG, mass = 14,056 ± 15) for controls. 
Figure 1 compares a representative mass spec-
trum obtained from a trauma patient within the 
fi rst 24 hours after injury with the mass spectrum 
of a healthy individual. The treatment with DTT 
of the immunoprecipitated TTR from the same 
patient resulted in a loss of microheterogeneity 
and a shift towards the native form of TTR.
No differences in molecular masses of the indi-
vidual signals were detected between controls and 
patients at different time points after injury, or 
between groups with or without modifi cation. 
However a transient change in the microheteroge-
neity was observed. The extent of modifi cation was 
defi ned on the basis of the relationship between 
peak height of the dominant cysTTR and the other 
variants as has been done previously (24, 26). In 
healthy persons the relation between cysTTR 
(100%) and cysglycTTR is 40%. A substantial 
change was thus defi ned if the extent of modifi ca-
tion of cysglyc reached values twice as high as in 
healthy controls. We therefore used 80% as a cut-
off. In 14 out of 18 multiple trauma patients a more 
dominant peak for the cysglycTTR (>80%) was 
present; this was again normalized at day 20 after 
hospitalization (Fig. 1). At this time point the TTR 
microheterogeneity pattern was comparable to 
healthy controls. Seven patients developed infec-
tion during their ICU stay and all of them showed 
an increased cysglycTTR modifi cation, whilst none 
of those without a high cysglycTTR actually devel-
oped infection. The peak height ratio in patients 
Table 1. General characteristics of ICU patients (n = 18) 
at day of admission.
Age (years)   32.2 ± 11.6
Sex 3 female/15 male
Height (cm) 179.3 ± 11.6
Weight (kg)   85.0 ± 10.7
Injury Severity Score (ISS) 45.2 ± 7.5
Abbreviated Injury Scale (AIS) 13.1 ± 2.1
Acute Physiology And Chronic  16.5 ± 8.2
Health Evaluation (APACHE II) 
Simplifi ed Acute Physiology   27.1 ± 9.5
Score (SAPS II) fi rst 24 hours 
SAPS II day 20 13.9 ± 7.9
Sepsis-related Organ Failure    7.9 ± 3.1
Assessment (SOFA) fi rst  
24 hours
SOFA day 20   1.7 ± 2.1
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within the fi rst 24 hours after injury was signifi cantly 
different to controls (Fig. 1). On day 20, no signif-
icant difference in peak height ratio was measured 
between patients and controls.
Trolox values were signifi cantly lower in patients 
with the modifi cation in TTR molecules in favor of 
the cysglyc form (3.1 mmol/L ± 0.4 versus 2.9 ± 0.3, 
p < 0.05); Trolox values were signifi cantly higher 
on day 20 after injury. Serum α-tocopherol levels 
were signifi cantly increased (p < 0.05) whilst for 
serum levels of carotenoids in total as well as for 
the individual carotenoids, except for β-carotene 
there was no difference between day 20 and the 
initial values at admission (Table 2).
Discussion
The detection and characterization of variants and 
modifi ed structures of proteins are clinically impor-
tant for diagnosis purposes and for the elucidation of 
the pathogenesis of various diseases. Modern mass 
spectrometry methods have largely replaced analyses 
by conventional protein chemistry. MALDI-TOF-MS 
after immunoprecipitation allows the measurement 
of the molecular weight of intact TTR and the eluci-
dation of the modifi ed structures. Post-translational 
modifi cations of TTR have enormous diagnostic 
value. Some variant proteins cause diseases, and some 
diseases result in increase of proteins with abnormally 
modifi ed structures. The protein TTR occurs in over 
100 variants and most of them cause amyloidosis 
(6, 7). A recently published study reported on differ-
ential post-translational modifi cations of TTR in 
Alzheimer’s disease (26). The results of our study 
demonstrate the link between polytrauma and a clear 
change in microheterogeneity of TTR. Although the 
exact consequence on the stability of TTR and the 
long term outcome of polytrauma patients remains 
to be elucidated, modifi cations may infl uence the 
interaction of TTR with other proteins (RBP, 
Thyroxin), as well as having an effect on many 
aspects of the metabolism of the protein such as 
receptor binding, tissue uptake, degradation and 
excretion.
A negative correlation between levels of CRP 
and TTR in serum has already been shown 
Table 2. The most important parameters used to characterize the antioxidative status and the post trauma 
response of ICU patients.
 First 24 hours Day 20 after  Modifi cation on  Without changes 
  injury cysGlysTTR in modifi cation
Trolox   2.8 ± 0.4a 3.1 ± 0.4 3.1 ± 0.4 2.9 ± 0.3
(mmol/L)    
α-tocopherol 17.4 ± 5.5b 22.3 ± 6.7 19.5 ± 7.3  19.3 ± 6.9
(µmol/L)    
α-carotene 0.04 ± 0.02 0.04 ± 0.03 0.03 ± 0.02 0.04 ± 0.03
(µmol/L)    
β-carotene 0.22 ± 0.10 0.23 ± 0.20 0.21 ± 0.14 0.20 ± 0.11
(µmol/L)    
Lutein 0.06 ± 0.02 0.04 ± 0.03 0.05 ± 0.03 0.04 ± 0.02
(µmol/L)    
Zeaxanthin 0.006 ± 0.002 0.004 ± 0.004 0.005 ± 0.003 0.004 ± 0.002
(µmol/L)    
Canthaxanthin  0.013 ± 0.005 0.006 ± 0.003 0.011 ± 0.006 0.010 ± 0.005
(µmol/L)    
β-cryptoxanthin  0.06 ± 0.03 0.04 ± 0.05 0.05 ± 0.03 0.04 ± 0.02
(µmol/L)    
Lycopene 0.06 ± 0.03 0.04 ± 0.02 0.05 ± 0.03 0.05 ± 0.03
(µmol/L)    
CRP 13.3 ± 8.4 6.1 ± 4.6  13.3 ± 9.0   12.3 ± 7.0
(mg/dL)    
Total carotenoids  0.5 ± 0.2 0.4 ± 0.3 0.4 ± 0.2 0.4 ± 0.2
(µmol/L)    
TTR 4.0 ± 2.6 4.1 ± 3.0 4.7 ± 3.4 3.5 ± 2.7
(µmol/L)    
aTrolox is signifi cantly different from patients with or without modifi cation (p < 0.05) and between both time points (p < 0.05).
bα-tocopherol tends to be different between patient within the fi rst 24 hours and on day 20 after injury.
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(Gericke et al. 2005). This is supported by our data 
from multiple trauma patients at the two time 
points. Due to the still increased CRP levels at day 
20 in comparison to healthy persons, a return of 
TTR to normal levels was also not observed 
(Table 2). In contrast, however, the amount of serum 
TTR in ICU patients on day 20 after injury differed 
signifi cantly from healthy controls (Table 2). These 
quantitative differences are in accordance with the 
decrease in serum levels associated with TTR that 
has been previously reported (Clark et al. 1996).
Despite the fact that no quantitative changes in 
serum TTR were present in the patient population 
an obvious difference in the microheterogeneity of 
the protein was found. Our results support and 
confi rm previous studies with regards to molecular 
variants of TTR in serum of humans (Terazaki et al. 
1998; Kiernan et al. 2002; Schweigert et al. 2004). 
In all samples the cysTTR was dominant.
No signifi cant difference in peak height ratio was 
found between patients and controls on day 20; 
however the modifi ed cysglycTTR tended to remain 
elevated. This corresponds to the still elevated serum 
levels of CRP and the still decreased serum levels 
of TTR. Interestingly, Trolox values were signifi -
cantly different in patients with the modifi cation in 
TTR molecules in favor of the cysglyc form, 
suggesting that oxidative stress might contribute to 
this specifi c microheterogeneity of TTR. Although 
Trolox values were signifi cantly higher on day 20 
after injury, indicating an improvement in oxidative 
status, serum antioxidants showed contradictory 
changes. While the increased α-tocopherol levels 
are comparable with those found in healthy persons, 
Figure 1. Representative mass spectra* of TTR in a healthy control (IA) and ICU patient after multiple trauma (IB). Control shows the native 
TTR (1 = 13,761 Da), the cysteinylated TTR (2 = 13,881 Da), the cysteinylglycinated TTR (3 = 13,937 Da) and the glutathionylated TTR 
(4 = 14,068 Da). In contrast, the serum TTR of a trauma patient (IB) shows a more dominant peak for the cysteinylglycinated TTR. Treatment 
with DTT (IC) resulted in a mass shift and native TTR remains the most dominant peak.
*Molecular weights resulted from internal calibration.
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carotenoid levels were substantially lower than in 
healthy well nourished individuals (Schweigert 
et al. 2003). Similar low levels have previously been 
observed in critically ill individuals (Weiss et al. 
1998). Lower serum levels of carotenoids have been 
demonstrated to be associated with a reduced dietary 
uptake or metabolic change in consequence of the 
acute phase response (Schweigert, 2001). Both 
aspects have to be considered with regard to the 
results of this study. In ICU patients receiving paren-
teral nutrition only α-tocopherol is routinely supple-
mented. Therefore, it can be assumed that tocopherol 
might have contributed to the slight improvement 
of antioxidative status at the end of this study.
Modifi cations in the microheterogeneity of 
TTR have been associated with oxidative stress 
(Kishikawa et al. 2002; Tajiri et al. 2002). The 
improvement of high-throughput analysis for 
these modifi cations has created increasing interest 
in the diagnostic relevance of such modifi cations 
in cases such as intoxications with molybdenum 
or the occurrence of protein modifi cation through 
homocysteine (Sass et al. 2003). Recently, the 
ratio of native to cysteinylated TTR in cerebro-
spinal fl uid has been suggested as a useful diag-
nostic tool for Alzheimer’s disease (Biroccio 
et al. 2006). In our patients, the cysglycTTR was 
associated with sepsis and was related to the 
antioxidative status.
Based on numerous studies, it can be assumed 
that the transient modifi cations in the microhetero-
geneity of TTR in our patients were of functional 
consequence. Most importantly, it has been demon-
strated that such modifications influence the 
amyloidogenicity of TTR (Kishikawa et al. 1999, 
Lim et al. 2003b). TTR is an important constituent 
among the more than 20 proteins and peptides iden-
tifi ed in different amyloid lesions (Westermark et al. 
1999). Alzheimer’s disease is characterized by two 
pathological hallmarks: extracellular- or senile 
amyloid plaques generated by the deposition of 
insoluble amyloid fi brils (Serpell, 2000) and intracel-
lular neurofi brillary tangles (Bossy-Wetzel et al. 
2004). These deposits are caused by accumulation 
of misfolded autologous proteins in tissues or organs 
(Merlini and Bellotti, 2003). With regards to TTR, 
the formation of TTR amyloid deposits is associated 
with the destabilization of the homotetramer complex 
which is either modifi ed by small molecules inter-
acting with the central binding site for thyroxin 
(Olofsson et al. 2001), or by the post-translational 
modifi cation at the Cys10 site of the molecule. This 
modifi cation, which possibly has a genetic cause, 
changes the three-dimensional structure and desta-
bilizes the complex (Zhang and Kelly, 2003). Modi-
fi cations such as the S-sulfonation and S-thiolation 
or an increase in doubly oxidized TTR were reported 
and had been linked to modifi cations of TTR as well 
as amyloid formation (Lim et al. 2003a) (Heegaard 
et al. 2006). At this stage it remains speculative, as 
to whether short term changes in the TTR microhet-
erogeneity may be indicative of an individual suscep-
tibility to destabilizing modifi cations in TTR, or 
whether transient changes might be of long term 
consequence for the affected ICU patient with regard 
to amyloidosis, Alzheimer’s disease, or the 
occurrence of other neurological disorders.
Conclusion
In conclusion, our results demonstrate that trauma 
associated transient changes in the microheteroge-
neity of TTR occurred in 78% of our ICU patients. 
This modifi cation was characterized by a transient 
abundance of the mixed disulfi de cysglycTTR. The 
context in which these changes occur, the extent to 
which such changes can be used for diagnostic 
purposes, as well as their role as a possible risk factor 
for the development of amyloidosis, Alzheimer’s 
disease or other diseases remains to be elucidated. 
It was, however, possible to demonstrate a link 
between the modulation of a multifunctional protein, 
infl ammation and the response after injury.
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